Imara, Inc. engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. Its product candidate, IMR-687 is a highly selective and small molecule inhibitor of PDE9. The company was founded by James G. McArthur in 2016 and is headquartered in Cambridge, MA.

As of 09/16/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  03/12/2020
Outstanding shares:  26,247,270
Average volume:  121,497
Market cap:   $113,913,152
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    45249V107
ISIN:        US45249V1070
Sedol:      BH4GV10
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.81
PS ratio:   0.00
Return on equity:   -72.90%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy